Lipo-anti-PD-L1-P4

Lipo-anti-PD-L1-P4 is an experimental targeted liposomal therapeutic consisting of progesterone (P4) encapsulated within a liposome that is surface-conjugated with an anti-programmed death-ligand 1 (PD-L1) antibody. Developed for the treatment of PD-L1-expressing cancers, such as triple-negative breast cancer (TNBC), the formulation utilizes the anti-PD-L1 antibody to direct the liposome to the tumor microenvironment and block PD-1/PD-L1 signaling. Once localized, the encapsulated progesterone is released to exert immune-regulatory effects, specifically reducing T-cell exhaustion and modulating the immune cell population by increasing CD8+ T-cell infiltration while decreasing B-cell and CD4+ T-cell proportions. This approach aims to achieve high local concentrations of progesterone to induce anticancer effects that are not possible at physiological levels, while minimizing systemic toxicity and peripheral tissue inflammation.

Other names

Liposome-encapsulated anti-PD-L1 antibody-conjugated progesteroneLipo-anti-PD-L1-progesteroneLipo-anti-PD-L-1-progesteroneLipo-anti-PD-L 1-progesterone